Protalix Biotherapeutics Valuation
| PLX Stock | USD 1.69 0.01 0.60% |
Based on Macroaxis valuation methodology, the company appears to be undervalued. Protalix Biotherapeutics holds a recent Real Value of $5.16 per share. The prevailing price of the company is $1.69. Our model determines the value of Protalix Biotherapeutics from analyzing the company fundamentals such as Return On Equity of -0.43, operating margin of (0.18) %, and Shares Outstanding of 73.63 M as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Protalix Biotherapeutics' valuation include:
Price Book 3.8137 | Enterprise Value 102.7 M | Enterprise Value Ebitda 5.6271 | Price Sales 3.2702 | Forward PE 2.6667 |
Undervalued
Today
Please note that Protalix Biotherapeutics' price fluctuation is relatively risky at this time. Calculation of the real value of Protalix Biotherapeutics is based on 3 months time horizon. Increasing Protalix Biotherapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Protalix Biotherapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Protalix Stock. However, Protalix Biotherapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.69 | Real 5.16 | Target 16.0 | Hype 1.66 |
The intrinsic value of Protalix Biotherapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Protalix Biotherapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Protalix Biotherapeutics helps investors to forecast how Protalix stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Protalix Biotherapeutics more accurately as focusing exclusively on Protalix Biotherapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Protalix Biotherapeutics' intrinsic value based on its ongoing forecasts of Protalix Biotherapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Protalix Biotherapeutics' closest peers.
Protalix Biotherapeutics Cash |
|
Protalix Valuation Trend
Analysing the historical paterns of Protalix Biotherapeutics' enterprise value and its market capitalization is a good way to estimate and gauge the value of Protalix Biotherapeutics over time and is usually enough for investors to make rational market timing decisions.
Protalix Biotherapeutics Total Value Analysis
Protalix Biotherapeutics is at this time expected to have company total value of 102.72 M with market capitalization of 124.44 M, debt of 26.28 M, and cash on hands of 17.11 M. Please note that company total value may be misleading and is a subject to accounting gimmicks. We encourage investors to carefully check all of the Protalix Biotherapeutics fundamentals before making security assessment based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
102.72 M | 124.44 M | 26.28 M | 17.11 M |
Protalix Biotherapeutics Investor Information
About 15.0% of the company outstanding shares are owned by corporate insiders. The book value of Protalix Biotherapeutics was at this time reported as 0.46. The company recorded a loss per share of 0.15. Protalix Biotherapeutics last dividend was issued on the 20th of December 2019. The entity had 1:10 split on the 20th of December 2019. Based on the key indicators related to Protalix Biotherapeutics' liquidity, profitability, solvency, and operating efficiency, Protalix Biotherapeutics may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter.Protalix Biotherapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Protalix Biotherapeutics has an asset utilization ratio of 77.57 percent. This suggests that the Company is making $0.78 for each dollar of assets. An increasing asset utilization means that Protalix Biotherapeutics is more efficient with each dollar of assets it utilizes for everyday operations.Protalix Biotherapeutics Ownership Allocation
Protalix Biotherapeutics owns a total of 73.63 Million outstanding shares. Protalix Biotherapeutics holds 14.53 pct. of its outstanding shares held by insiders and 5.2 pct. owned by third-party entities. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.Protalix Biotherapeutics Profitability Analysis
The company reported the last year's revenue of 65.49 M. Total Income to common stockholders was 8.31 M with profit before taxes, overhead, and interest of 28.05 M.About Protalix Biotherapeutics Valuation
Our relative valuation model uses a comparative analysis of Protalix Biotherapeutics. We calculate exposure to Protalix Biotherapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Protalix Biotherapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 42.5 M | 44.6 M | |
| Pretax Profit Margin | 0.13 | 0.12 | |
| Operating Profit Margin | 0.16 | 0.17 | |
| Net Profit Margin | 0.13 | 0.13 | |
| Gross Profit Margin | 0.65 | 0.68 |
Protalix Biotherapeutics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 82.4 M | |
| Quarterly Earnings Growth Y O Y | -0.392 | |
| Forward Price Earnings | 2.6667 |
Protalix Biotherapeutics Current Valuation Indicators
Valuation refers to the process of determining the present value of Protalix Biotherapeutics and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Protalix we look at many different elements of the entity such as Protalix's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Protalix Biotherapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Protalix Biotherapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Protalix Biotherapeutics' worth.Additional Tools for Protalix Stock Analysis
When running Protalix Biotherapeutics' price analysis, check to measure Protalix Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protalix Biotherapeutics is operating at the current time. Most of Protalix Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Protalix Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protalix Biotherapeutics' price. Additionally, you may evaluate how the addition of Protalix Biotherapeutics to your portfolios can decrease your overall portfolio volatility.